Abstract: Several substituted α-alkoxy phenyl propionic acids were synthesized, and their hypotriglyceridemic properties were evaluated in Swiss albino mice. Some of the compounds showed excellent triglyceride-and cholesterol-lowering properties even at a dose of 1 mg/kg. 2,5-Substituted pyrrole-containing heterocycles were among the most potent alkoxy propionic acid class of compounds. These compounds also showed excellent antidiabetic activities in animal models.
Both the compounds 12 and 13 have bulky substituents, which are not favorable for binding to the PPAR α and γ receptors (unpublished results). Therefore, we carried out a gradual structural modification to generate a structure-activity relationship. This led us to arrive at the suitable substituents around the pyrrole ring. The results, which are compiled in Table 1 , show that tetra-and tri-substituted pyrroles (12, 13, 15) do not reduce serum TGs in Swiss albino mice. Thus, we synthesized 1,4-disubstituted pyrrole derivatives. Although compounds 14 and 17 did not show serum TG reduction, the TG reductions shown by 16 (26 % at 10 mg/kg dose) and 18 (31 % at 10 mg/kg dose) were encouraging. At present, we are not able to understand the rationale for certain 1,4-disubstituted compounds (15, 17) to increase the serum TG levels and TC, whereas in certain other 1,4-substituted compounds, reduction of TG and TC were found in Swiss albino mice. We further studied the activity of 1,4-dialkylated pyrrole derivatives 19 and 20, which showed 53 % reduction in TG at 10 mg/kg dose and 41 % reduction in TG at 3 mg/kg dose, respectively. The unsubstituted pyrrole derivative 21 showed very poor activity. When the isopropyl group in 19 is replaced with a methyl group, the resulting compound 22 reduced serum TG up to 27 % even at 1 mg/kg dose in contrast to compound 19 (6 % TG reduction at 1 mg/kg dose). The compound 23 having 1-methyl-4-phenyl pyrrole moiety also showed good TG-and TC-reducing activity.
This encouraged us to examine the compounds having a methyl group in the 1-position and variously substituted phenyl group in the 4-position of pyrrole moiety (Table 2) .
Compound 24 with 1-methyl-4-(4-fluoro-phenyl)pyrrole moiety reduced 53 % TG at 1 mg/kg dose. Introduction of a methyl group at 4-, 3-, or 2-position in the phenyl substituent of 23 to generate 25-27, respectively, led to good TG reduction. Also, methoxy group in the 3-(28) as well as 4-position (29) resulted in very good TG and TC reduction. However, the 4-OH group in compound 30 led to decreased TG-reducing activity and no cholesterol-reducing activity. When a 4-benzyloxy group was introduced in place of the 4-OH group, the TG-and TC-reducing activities were restored (31, 52 % TG reduction and 32 % TC reduction). On the other hand, 3-benzyloxy group in 32 as well as cyclohexylmethoxy group as in 35 destroyed such activity. Introduction of a second methoxy group at 3-position of phenyl group in 29 leading to compound 33 again destroyed the TG-and TC-reducing activity of 29. Interestingly, compound 34 with 3,4-dioxymethylene moiety on the phenyl ring reduced both TG and TC effectively (63 % TG and 26 % TC reduction at 3 mg/kg dose). An electron-withdrawing moiety 4-mesylate (36) in place of 4-OH group in 30 did not alter the TG-reducing activity. Replacing the phenyl group in 23 with a pyridyl group exhibited TG-reducing activity dependent on the place of attachment of the pyridyl group to the pyrrole moiety. While 2-pyridyl group (37) showed 60 % reduction in TG at 3 mg/kg dose in Swiss albino mice, 4-pyridyl (39) reduced TG moderately (29 %) and 3-pyridyl group (38) showed no such activity. 2-Napthyl group (41) in place of phenyl group in 23 gave 38 % reduction in TG, whereas 1-naphthyl group (40) even at 10 mg/kg dose reduced only 5 % TG.
Based on the TG-and TC-reducing activities observed in single-dose studies, compounds 23, 29, 31, and 34 were selected for a multiple-dose study to evaluate their effect with increasing dose. Male Swiss albino mice were treated for 6 days with the selected compounds, and their effect on TG and serum TC reduction is tabulated in Table 3 . Both TG and serum TC were reduced in a dose-dependent manner. It is interesting to note that although the effect on TG lowering is seen starting from the lowest dose of 0.1 mg/kg, the reduction in cholesterol is observed at the highest dose taken in all the cases except 31, wherein 18.9 % reduction in serum cholesterol is found even at 1 mg/kg dose. The cholesterol reduction achieved with these four compounds is quite high (20-25 %) in this animal model. Looking at the very good activity in hypertriglyceredemic mice, we decided to study these compounds 29, 31, and 34 in genetic models of diabetes and obesity. Thus, hyperglycemic male db/db mice (6-8 weeks old) were treated at 1 mg/kg dose for 6 days with 29, 31, and 34. All of the compounds showed comparatively very good activities of serum glucose reduction and serum TG reduction (Table 4) . The compounds 29, 31, and 34 have been taken for further studies in other animal models of diabetes, obesity, and insulin resistance. Studies to establish the mechanism of action of these drugs through which they lower serum TG, glucose, and TC are under progress.
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